Does Mefloquine Interact with Pyridostigmine Bromide?
CDI records a moderate classification for Mefloquine and Pyridostigmine Bromide. The stored summary is: Additive effects on gastrointestinal tract (loose bowels) and atrial rate with concomitant use. The mechanism involves additive effect on gi tract and cardiac conduction. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Moderate
- Management
- Monitor for effects
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
Additive effect on GI tract and cardiac conduction
What To Tell Your Doctor or Pharmacist
If you are taking Mefloquine and your doctor is considering prescribing Pyridostigmine Bromide (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider